LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

LLY

1,027.89

+1.84%↑

JNJ

246.11

+1.4%↑

ABBV

228.83

+3.13%↑

NVS

169.84

+3.23%↑

MRK

122.85

+3.02%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

4.26 3.15

Buy Sell

Overview

Share price change

24h

Current

Min

4.02

Max

4.29

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+274.82% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-56M 199M
Previous open	1.11
Previous close	4.26

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 lut 2026, 22:04 UTC

Earnings

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 lut 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 lut 2026, 23:32 UTC

Earnings

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 lut 2026, 23:19 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 lut 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 lut 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26 lut 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:13 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 lut 2026, 21:59 UTC

Earnings

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 lut 2026, 21:58 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 lut 2026, 21:49 UTC

Earnings

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 21:45 UTC

Earnings

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 lut 2026, 21:44 UTC

Earnings

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 lut 2026, 21:44 UTC

Earnings

Coles Expects Market to Remain Highly Competitive

26 lut 2026, 21:44 UTC

Earnings

Coles Says Supermarket Customers Remain Value Oriented

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 lut 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 lut 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

274.82% upside

12 Months Forecast

Average 15.33 USD 274.82%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.